Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma: Ratain MJ, Eisen T. Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai A, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B. O’Dwyer PJ, University of Chicago, Chicago, IL

Autor: Russo, Paul
Zdroj: In Urologic Oncology: Seminars and Original Investigations 2006 24(6):560-560
Databáze: ScienceDirect
Externí odkaz: